Skip to content

Efficacy and safety of Siddha medicine vs. iron folic acid for iron deficiency anemia in women of reproductive age

Efficacy and safety of Siddha regimen for management of mild to moderate iron deficiency anaemia amongst reproductive age-group women as compared to iron folic acid supplements: An open labelled, multicentric randomized controlled trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/01/079620
Enrollment
170
Registered
2025-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E611- Iron deficiency

Interventions

Intervention1: Siddha Regimen: 1. ArakkuThailam- 50 ml 2. Naakku Poochi Kudineer -30 ml HS 3. Bavana Kadukkai- 2-tab B.D 4. Aya Bringaraja Paanitham 15 ml B.D Control Intervention1: Allopathic regim

Sponsors

National Institue of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women of reproductive age group from 18 to 49 years with mild to moderate iron deficiency anemia Serum ferritin lesser than 30 mcg per dL Should consent to receive any type of intervention before randomization Not participating in any other research study

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Women planning for pregnancy in the next 3 months at the time of screening Known case of anaemia due to other causes including thyroid dysfunction and anaemia of chronic diseases Known diabetics on anti-diabetic drugs Those who have HbA1C greater than 7 Those who are already consuming IFA more than 14 days Known allergy to iron and ingredients of Siddha regimen Patient with known chronic kidney and liver disease Any other condition in advice of treating doctor that is putting participant on risk due to study participation

Design outcomes

Primary

MeasureTime frame
The average change in Hb level at timepoint one two and 3 months as compared to baseline Average change in Serum iron Total Iron binding capacity Ferritin Transferrin saturation levels at baseline and 3 months Average RBC MCV MCH and MCHC levels at timepoint 1 2 and 3 months as compared to baseline Association of Mukkutram categories at baseline with Hb improvement Timepoint: Baseline 15th day end of one two and 3 months

Secondary

MeasureTime frame
Proportions of treatment emergent adverse eventsTimepoint: Baseline, 15days, 30days, 60days, 90days

Countries

India

Contacts

Public ContactDrPShanmugapriya

National Institute of Siddha

sppriyaathamu@gmail.com09962513101

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026